PT2385

Catalog No.S8352

For research use only.

PT2385 is a HIF-2α antagonist with luciferase EC50 of 27 nM and no significant off-target activity.

PT2385 Chemical Structure

CAS No. 1672665-49-4

Selleck's PT2385 has been cited by 4 Publications

Purity & Quality Control

Choose Selective HIF Inhibitors

Other HIF Products

Biological Activity

Description PT2385 is a HIF-2α antagonist with luciferase EC50 of 27 nM and no significant off-target activity.
Targets
HIF-2α [1]
(Cell-free assay)
27 nM(EC50)
In vitro

PT2385 blocks HIF-2α dimerization with the HIF1α/2α transcriptional dimerization partner ARNT/HIF1β. PT2385 inhibits the expression of HIF2α-dependent genes, including VEGF-A, PAI-1, and cyclin D1 in ccRCC cell lines and tumor xenografts. PT2385 has no effect on the proliferation or viability of 786-O and A498 cells in culture at concentration as high as 10 μmol/L. Treatment of 786-O cells with PT2385 significantly reduces the levels of mRNA for CCND1, VEGF-A, GLUT1, and PAI-1 in a concentration-dependent manner. Treatment of Hep3B cells with PT2385 reduces hypoxia-induced expression of erythropoietin (EPO) and PAI-1, both known HIF2α target genes[2].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
786-O NH3OTZBHfW6ldHnvckBie3OjeR?= Mm\JNlQhcHK| NUDVeVk6SW62YXfvcol{fCCjY4Tpeol1gSCjdDDITWYuOmGucHjhJIlvKGi3bXHuJFc5Pi2RIHPlcIx{KGOxLXX4dJJme3OrbnegTGlHKHKnc4DvcpNqfmViZXzlcYVvfCCjZoTldkAzPCCqcoOgZpkhV06HLVfsc{BtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVAhRSByLkCyO{DPxE1w NFfuUGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEK4PVcyPid-M{CyPFk4OTZ:L3G+
786-O Ml7ySpVv[3Srb36gZZN{[Xl? M2DlXlI1KGi{cx?= MmHWRY51[WexbnnzeEBi[3Srdnn0fUBifCCKSV[tNoFteGijIHnuJIh2dWGwIEe4Ok1QKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDWSWdHSSClb37j[Y51emG2aX;uJIFnfGW{IEK0JIhzeyCkeTDFUGlUSSxiRVO1NEA:KDBwMESxJO69VS5? Mlr3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{OEm3NVYoRjNyMki5O|E3RC:jPh?=
786-O M3PCTmZ2dmO2aX;uJIF{e2G7 M1vKc|I1KGi{cx?= MkjJRY51[WexbnnzeEBi[3Srdnn0fUBifCCKSV[tNoFteGijIHnuJIh2dWGwIEe4Ok1QKGOnbHzzJIF{e2W|c3XkJIF{KG[{ZXWgdIxie22jIHHkbpV{fGWmIFXDOVAh\m:{IILl[JVkfGmxbjDpckBXTUeIQTDjc45k\W62cnH0bY9vKGGodHXyJFI1KGi{czDifUBGVEmVQTygSWM2OCB;IECuNVU5KM7:TT6= MlnlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{OEm3NVYoRjNyMki5O|E3RC:jPh?=
786-O NW\DVIh2TnWwY4Tpc44h[XO|YYm= MUmxNEBu\y:tZx?= M1v6O|Mh\GG7cx?= NV;QcYNJUW5idnn2c{BqdmirYnn0bY9vKG:oIFjJSk0z[WyyaHGgbY4hW0OLRD;CbYVo\SCvb4Xz[UB5\W6xZ4Lh[pRm\CC5aYToJIh2dWGwIEe4Ok1QKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDDR25FOSCvUl7BJIxmfmWuczDheEAyOCCvZz;r[{wheG9iYnnkJIZweiB|IHThfZMh[W6mIH3lZZN2emWmIHHmeIVzKDF{IHjyd{Bxd3O2IHzhd5Qh\G:|ZTDifUByWlRvUFPSJIFv[Wy7c3nz M1zTN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMki5O|E3Lz5|MEK4PVcyPjxxYU6=
786-O MoToSpVv[3Srb36gZZN{[Xl? M17nR|ExKG2pL3vn MX[zJIRigXN? M4DNcWlvKH[rdn:gbY5pcWKrdHnvckBw\iCKSV[tNoFteGijIHnuJHNEUURxQnnl[4UhdW:3c3WgfIVvd2e{YX\0[YQhf2m2aDDoeY1idiB5OE[tU{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iVlXHSmEhdVKQQTDs[ZZmdHNiYYSgNVAhdWdxa3esJJBwKGKrZDDmc5IhOyCmYYnzJIFv\CCvZXHzeZJm\CCjZoTldkAyOiCqcoOgdI9{fCCuYYP0JIRwe2ViYomgdXJVNVCFUjDhcoFtgXOrcx?= Ml;VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{OEm3NVYoRjNyMki5O|E3RC:jPh?=
786-O NULoOVJ{SW62aYT1cY9zKGG|c3H5 NHfwbm0yOCCvZz;r[y=> MnfkNlEh\GG7cx?= M4C2SmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIEe4Ok1QKGOnbHzzJJhmdm:pcnHmeIVlKGmwIGPDTWQwSmmnZ3WgcY92e2ViYYPz[ZN{\WRiYYOgeJVud3JicnXndoV{e2mxbjDheEAyOCCvZz;r[{wheG9iYnnkJIZweiB{MTDkZZl{ MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ6OUexOkc,OzB{OEm3NVY9N2F-
786-O NYW0[VN1TnWwY4Tpc44h[XO|YYm= M3fBe|ExKG2pL3vn MWOzJIRigXN? MkLwUYlvcW23bTDkdpVoKGyndnXsJIlvKFOFSVSvRolm\2VibX;1d4UhgGWwb3fyZYZ1\WRid3n0bEBpfW2jbjC3PFYuVyClZXzsd{BifCBzMDDt[{9s\yxicH:gZollKG[xcjCzJIRigXNiYX7kJI1m[XO3cnXkJIFnfGW{IEGyJIhzeyCyb4P0JIxie3RiZH;z[UBjgSCOQz3NV{9OWyCjbnHsfZNqew>? M3PpSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMki5O|E3Lz5|MEK4PVcyPjxxYU6=
786-O NGntdWNHfW6ldHnvckBie3OjeR?= NFG5R4QyOCCvZz;r[y=> MkXRN{Bl[Xm| M1j6Z2lvKH[rdn:gbY5pcWKrdHnvckBw\iCKSV[tNoFteGijIHnuJHNEUURxQnnl[4UhdW:3c3WgfIVvd2e{YX\0[YQhf2m2aDDoeY1idiB5OE[tU{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5idIXtc5Ih\GW{aY\l[EBXTUeIQTDwdo91\WmwIHzleoVteyCjdDCxNEBu\y:tZzygdI8h[mmmIH\vdkA{KGSjeYOgZY5lKG2nYYP1doVlKGGodHXyJFEzKGi{czDwc5N1KGyjc4Sg[I9{\SCkeTDFUGlUSQ>? M4j6SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMki5O|E3Lz5|MEK4PVcyPjxxYU6=
In vivo

PT2385 exhibits good mouse oral bioavailability (110%) and low to medium in vivo clearance. In mice administrated via intravenous injection, the t1/2 of PT2385 is 3.3 h. In rat pharmacokinetics studies, the oral bioavailability (F) when dosed at 10 mg/kg is 40% and the t1/2 is 3.3 h. In dogs, the oral bioavailability (F) is 87% and the t1/2 is 11 h[1]. Treatment of tumor-bearing mice with PT2385 causes dramatic tumor regressions (clear cell renal cell carcinomas). PT2385 exhibits no adverse effect on cardiovascular performance[2].

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: 786-O cells
  • Concentrations: 20, 6.67, 2.22, 0.74, 0.25, 0.082, 0.027, 0.009, 0.003, 0.001 μM
  • Incubation Time: 44 h
  • Method:

    About 7500 of 786-O cells in 180 μL of growth medium are seeded into each well of a 96 well plate with white clear bottom on the first day. Four hours later, serial dilutions of 10x compound stocks are made in growth medium from 500x DMSO stocks, and 20 μL of those 10x stocks are added to each well to make final concentrations as follows (μM): 20, 6.67, 2.22, 0.74, 0.25, 0.082, 0.027, 0.009, 0.003, 0.001, and 0. Each concentration has duplicated wells. About 20 hours later, medium is removed by suction and each well is supplied with 180 μL of growth medium. About 20 μl freshly-made 10x compound stocks are added to each well. About 24 hours later, cell culture medium is removed for the determination of VEGFA concentration using an ELISA kit.

Animal Research:

[1]

  • Animal Models: male CD1 mice
  • Dosages: 3 mg/kg (IV) and 10 mg/kg (PO)
  • Administration: IV or PO

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 383.34
Formula

C17H12F3NO4S

CAS No. 1672665-49-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CS(=O)(=O)C1=C2C(C(CC2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)(F)F)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02553356 Completed Drug: PT2385 Healthy Peloton Therapeutics Inc. September 2015 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy PT2385 | PT2385 supplier | purchase PT2385 | PT2385 cost | PT2385 manufacturer | order PT2385 | PT2385 distributor